While previous studies have primarily focused on biomarkers like PD-L1 (2), tumor mutational burden (5), and tumor infiltrating lymphocytes (5) to assess tumor response, there is a continued need for reliable clinicopathological factors for postoperative risk stratification. The gene discussed is CD274; the disease is neoplasm.